Altimmune, Inc. - Common Stock (ALT) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2018 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
ALT on Nasdaq
Shares outstanding
104,413,190
Price per share
$5.10
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
54,382,978
Total reported value
$196,383,177
% of total 13F portfolios
0%
Share change
+13,013,494
Value change
+$46,868,534
Number of holders
175
Price from insider filings
$5.10
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Altimmune, Inc. - Common Stock (ALT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 9.1% $38,439,194 9,491,159 The Vanguard Group 31 Dec 2025
BlackRock, Inc. 7.6% -12% $23,736,362 -$100,148 6,133,427 -0.42% BlackRock, Inc. 30 Jun 2025
AMERIPRISE FINANCIAL INC 1.9% -79% $7,306,296 -$19,283,488 1,443,932 -73% Ameriprise Financial, Inc. 31 Mar 2025

As of 31 Dec 2025, 175 institutional investors reported holding 54,382,978 shares of Altimmune, Inc. - Common Stock (ALT). This represents 52% of the company’s total 104,413,190 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Altimmune, Inc. - Common Stock (ALT) together control 45% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 9.3% 9,704,298 +52% 0% $35,032,515
VANGUARD GROUP INC 9.1% 9,491,159 +49% 0% $34,263,084
STATE STREET CORP 4.9% 5,119,703 +42% 0% $18,482,128
GEODE CAPITAL MANAGEMENT, LLC 2.2% 2,292,410 +14% 0% $8,277,782
TANG CAPITAL MANAGEMENT LLC 2% 2,131,307 0% 0.38% $7,694,018
JANE STREET GROUP, LLC 1.7% 1,783,950 +537% 0.01% $6,440,060
SUSQUEHANNA INTERNATIONAL GROUP, LLP 1.3% 1,369,017 -0.38% 0.01% $4,942,151
MORGAN STANLEY 1.3% 1,359,885 -8.8% 0% $4,909,186
GOLDMAN SACHS GROUP INC 1.3% 1,349,293 +140% 0% $4,870,948
D. E. Shaw & Co., Inc. 1.3% 1,343,583 +273% 0% $4,850,335
CITADEL ADVISORS LLC 1.3% 1,337,927 +4.4% 0% $4,829,917
TWO SIGMA INVESTMENTS, LP 1.2% 1,265,683 -37% 0.01% $4,569,116
Nuveen, LLC 1.2% 1,244,211 +515% 0% $4,491,602
Knoll Capital Management, LLC 1.1% 1,121,524 0% 1.9% $4,048,701
MARSHALL WACE, LLP 0.88% 922,777 0% $3,331,226
TWO SIGMA ADVISERS, LP 0.76% 793,900 -44% 0.01% $2,865,979
NORTHERN TRUST CORP 0.69% 715,991 +9% 0% $2,584,727
UBS Group AG 0.61% 642,048 -0.12% 0% $2,317,793
FMR LLC 0.54% 564,093 +27% 0% $2,036,376
SCHRODER INVESTMENT MANAGEMENT GROUP 0.45% 469,013 0% $1,693,137
BARCLAYS PLC 0.38% 400,595 +18% 0% $1,446,149
Soviero Asset Management, LP 0.38% 400,000 0.75% $1,444,000
BANK OF AMERICA CORP /DE/ 0.37% 383,783 +20% 0% $1,385,456
Beirne Wealth Consulting Services, LLC 0.36% 376,458 -8.3% 0.39% $1,359,014
Bank of New York Mellon Corp 0.34% 354,201 +3.6% 0% $1,278,666

Institutional Holders of Altimmune, Inc. - Common Stock (ALT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 54,382,978 $196,383,177 +$46,868,534 $3.61 175
2025 Q3 41,476,255 $156,373,200 +$14,303,370 $3.77 157
2025 Q2 37,594,851 $145,435,659 -$6,199,092 $3.87 179
2025 Q1 38,134,819 $190,969,777 -$15,358,703 $5.00 173
2024 Q4 40,453,394 $291,649,491 +$7,414,850 $7.21 180
2024 Q3 39,490,913 $242,642,286 -$19,754,298 $6.14 167
2024 Q2 42,376,353 $281,796,522 -$21,723,923 $6.65 173
2024 Q1 44,351,359 $451,471,154 +$108,533,821 $10.18 166
2023 Q4 33,518,969 $377,122,817 +$87,837,677 $11.25 142
2023 Q3 30,119,653 $78,312,976 -$14,266,982 $2.60 110
2023 Q2 35,266,907 $124,503,782 -$30,995,734 $3.53 118
2023 Q1 40,146,839 $169,418,214 -$115,027,226 $4.22 129
2022 Q4 46,782,400 $769,520,216 +$29,466,534 $16.45 122
2022 Q3 46,027,433 $587,716,469 +$80,574,668 $12.77 116
2022 Q2 39,903,915 $466,872,641 +$78,793,572 $11.70 102
2022 Q1 33,651,643 $207,371,526 +$5,868,022 $6.09 96
2021 Q4 32,470,413 $295,787,573 -$27,220,088 $9.16 98
2021 Q3 32,076,209 $363,055,937 +$59,058,531 $11.31 113
2021 Q2 27,191,172 $267,846,675 +$16,710,421 $9.85 102
2021 Q1 23,819,490 $336,535,131 +$49,552,065 $14.13 92
2020 Q4 20,471,521 $230,916,860 -$28,712,052 $11.28 83
2020 Q3 21,898,188 $289,049,000 +$115,723,197 $13.20 67
2020 Q2 13,311,955 $142,567,171 +$125,471,540 $10.71 53
2020 Q1 1,583,373 $5,082,210 +$1,206,160 $3.21 20
2019 Q4 1,281,842 $2,423,890 +$314,812 $1.89 21
2019 Q3 1,113,862 $2,171,952 +$159,903 $1.95 22
2019 Q2 1,032,457 $2,456,382 -$456,118 $2.37 15
2019 Q1 1,114,198 $3,229,903 +$1,231,709 $2.90 13
2018 Q4 806,802 $1,663,208 +$928,520 $2.06 16
2018 Q3 193,862 $853,444 +$853,440 $4.40 7